DENTSPLY SIRONA Inc

Latest Results (18.05.2026):

DENTSPLY SIRONA Inc. reported results for the fourth quarter of 2025 (Q4 2025). Net sales for Q4 2025 were $961 million (up 6.2% year‑over‑year; +2.5% on a constant‑currency basis). The company reported a GAAP net loss attributable to shareholders of $146 million, or a diluted loss per share of $0.74, driven primarily by goodwill and intangible asset impairments (reported as $144 million net of tax). On a non‑GAAP basis, Q4 2025 adjusted EPS was $0.27. Management announced a restructuring and a change in capital allocation, and provided a FY 2026 outlook (see highlights).

Sales

Q4 2025 net sales were $961M (+6.2% reported; +2.5% constant currency). FY 2025 net sales were $3.68B, down 3.0% reported (−4.3% constant currency), with segment trends varying (Connected Technology Solutions, Essential Dental Solutions, Orthodontic & Implant Solutions split provided in the release).

Profitability & GAAP EPS

Q4 2025 GAAP results: operating loss of $139M and GAAP net loss attributable to shareholders of $146M (diluted loss per share $0.74). The quarter’s GAAP loss was materially impacted by non‑cash goodwill and intangible asset impairments (reported as $144M net of tax in the release).

Adjusted / Non‑GAAP Results

On a non‑GAAP basis Q4 2025 adjusted gross margin was 49.8%, adjusted operating income was $86M, adjusted net income attributable was $55M, and adjusted EPS was $0.27. Adjusted EBITDA for Q4 2025 was $135M (margin 14.1%). For FY 2025, adjusted EBITDA was $667M (margin 18.1%) and adjusted EPS was $1.60 (twelve‑month adjusted figures shown in the release).

Cash Flow & Balance Sheet

Q4 2025 free cash flow was $60M (net cash from ops $101M less capex $41M). FY 2025 free cash flow was $104M (net cash provided by ops $235M less capex $131M). Cash and cash equivalents at 12/31/2025 were $326M. Long‑term debt increased to $2,015M; total equity declined to $1,340M from $1,943M year‑over‑year.

Restructuring & Capital Allocation

The company announced a restructuring to redirect approximately $120M annually into its Return‑to‑Growth Action Plan (focus on innovation, clinical education, and sales enablement). DENTSPLY SIRONA also eliminated its quarterly cash dividend to redeploy capital toward debt reduction and share repurchases.

Outlook for FY 2026

For full year 2026 the company provided non‑GAAP guidance: expected net sales of $3.5B–$3.6B and adjusted EPS of $1.40–$1.50. The company noted it cannot provide a GAAP earnings estimate due to uncertainty around potential items (e.g., restructuring, impairments).

Strategic / Corporate Items

Management highlighted distribution agreements (Patterson Dental, Benco, Burkhart, A‑dec), launched a new Surity™ Female External Catheter product in the U.S., and added three directors to the board (James Forbes, Brian McKeon, Don Zurbay) to support execution.